Malloy Kirk 4

What Happened
Malloy Kirk, a director of Rapid Micro Biosystems (RPID), participated in a registered direct offering on May 29, 2026 and acquired 12,787 shares of Class A common stock for approximately $1.96 per share (total reported $24,999). At the same time he received accompanying Series A and Series B warrants (each covering 12,787 shares or pre-funded warrants in lieu) issued in connection with the same purchase. The filing lists these as grant/acquisition transactions (code A); this is a purchase/acquisition rather than a sale.

Key Details

• Transaction date: May 29, 2026; Form 4 filed June 2, 2026 (filed within the standard 2-business-day reporting window).
• Price: filing shows $1.96 per share (total $24,999); footnote states the purchase price was $1.955 per share for each share and accompanying warrants.
• Securities received: 12,787 shares + Series A and Series B warrants covering 12,787 shares each (or pre-funded warrants in lieu). Two warrant entries are reported as derivative acquisitions at $0.00 (reflecting issuance accompanying the share purchase).
• Shares owned after transaction: Not specified in the provided Form 4 excerpt.
• Footnotes of note: (F1) purchase was via a registered direct offering and approved by the company’s compensation committee under Rule 16b-3; (F2) some shares are held in a family trust where the reporting person shares investment power and family members are beneficiaries; (F3) the Series A/B warrants include an exercise limitation — they cannot be exercised if the resulting beneficial ownership would exceed 4.99% of outstanding Class A shares.

Context
This was an outright purchase/accompanying-warrant issuance (not an option exercise or sale). Purchases by directors can be interpreted by some investors as alignment with the company, but filings are factual records of transactions and do not state motives. The warrants and their 4.99% ownership cap are important for understanding dilution and exercise constraints.